Short term effects of raloxifene on coagulation profile

Yıl 2005, Cilt: 36 Sayı: 2, 61 - 64, 01.03.2005

Deniz Köse Hüsamettin Uslu Özay Oral Semih Tuğrul Akif Alkan Arzu Aydın

Öz

Objective: To evaluate the short term effects of Raloxifene use on coagulation profile. Materials and Methods: 51 patients who were followed prospectively in our menopause clinic during October 2002 - January 2004 had been evaluated. All the patients had been given 60 mg Raloxifene single dose daily for 6 months. Pretreatment and 6th month serum fibrinogen, Activated Partial Thromboplastin Time (APTT), Prothrombin Time(PT) and platelet values were recorded and statistical analysis were made by paired samples t-test in SPSS version 11,5. Results: Mean patient age was 54.1 7.67 years and mean menopause age was 7.1 5.7years. No statistically significant differences were found in terms of serum APTT, PT and fibrinogen levels in pre and post treatment groups. A significant decrease in the number of platelets was recorded in the serum samples on the 6th month, (p =0,001) Conclusion: We found that Raloxifene use dose not have a short term significant effect on coagulation parameters.

Anahtar Kelimeler

Raloxifene, Prospective Studies, Postmenopause, Blood Coagulation

Raloksifen Hcl tedavisinin koaglasyon profiline etkisi

Öz

Amaç: Raloksifen HC1 tedavisinin koagulasyon profili üzerine olan erken dönem etkilerinin araştırılması. Gereç ve Yöntem: Kliniğimiz menopoz polikliniğinde Ekim 2002-Ocak 2004 tarihleri arasında prospektif olarak takip edilen 51 postmenopozal hasta çalışmaya dahil edilmiştir. Tüm hastalar 6 ay boyunca günde tek doz 60 mg Raloksifen HC1 kullanmışlardır. Bazal ve 6. ay serum fibrinojen, Aktive Parsiyel Trombophstin Zamanı(APTT), Protrombin Zamam(PT) ve trombosit değerleri kayıt edilip, SPSS 11.5 ile eşlendirilmiş örneklemde t-testi kullanılarak istatistiksel olarak karşılaştmlmıştır. Bulgular: Çalışmada ortalama hasta yaşı 54,1 7,6 ve ortalama menopoz yaşı 7,1 5,7 idi. Serum fibrinojen, APTT ve PT bazal ve 6. ay değerleri arasında anlamlı bir fark saptanmazken, trombosit sayısının 6. ayda anlamlı olarak azaldığı tespit edilmiştir (p = 0,001). Sonuç: Biz çalışmamızda Raloksifen HC1 kullanımının erken dönemde koagulasyon profili üzerinde anlamlı bir değişiklik yapmadığını saptadık.

Anahtar Kelimeler

Raloksifen, İleriye dönük çalışma, Postmenopoz, Kan pıhtılaşması

Kaynakça

• 1.Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menapause and risk of cardiovascular disease: the Framingham study. Ann Intern Med
• 1976; 85: 447-52 2.Richelson LS, Wahner HW, Melton LJ 3rd, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Eng J Med 1984; 311:1273-75 3.Byyay RL, SperoffL. A clinical guide for the care of older women, primary and preventive care
• Baltimore Williams & Wilkins. 1996 4.Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ. Patient-spesific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277; 1140-7 5.Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80 6.Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3 7.Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliari A. Hormone replacement therapy and risk of venous thromboembolism:population based case-control study. BMJ. 1997; 314: 796-800 8.Varas Lorenzo C, Garda Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez Gutthann S
• Hormone replacement therapy and risk of hospitalisation for venous thromboembolism: a population-based study in Southern Europe. Am J Epidemiol. 1998; 147: 387-90 9.Kauffman RF, Bryant Hu. Selective estogen receptor modulators. Drug News Perspect 1995; 8: 531-39 10.Mitlak BH, Cohen FJ. In search of optimal long- term female hormone replacement: the potential of selective estogen receptor modulators. Horm Res
• 1997; 48: 155-63 11.Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA. Continued breast cancer risk reduction in postmenopausal women treared with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001; 65: 125-34
• 12.Silverstein MD, Heit JA, Mohr DN, Petterson Tm, O'Fallon WM. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25- year population based study. Arch Intern Med
• 1998; 158: 585-93
• 13.Grodstein F,Stampfer MJ,Goldhaber SZ, Manşon JE, Colditz GA. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7
• 14.Yang NN, Venugopalan M, Hardikar S, GlasebrookA. Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene. Science. 1996; 273: 1222-5
• 15.Kennel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997; 54: 32-40 16.Walsh WB, Küller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-1451
• 17.Shand B, Gilchrist N, Blackwell T, March R
• The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial. Clinical Hemorheology and Microcirculation. 2002; 26:249-55 18.O'Neill ŞM, Eden J, Baber R, Ekangaki A, Stocks JM, Wolthers T, Davis SR. Transition to raloxifene with and without .low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen a pilot study. Climacteric. 2003; 6: 347-53